Pancreatic cancer trials recruiting in Maryland
All Pancreatic cancer trials nationally
58
Recruiting in Maryland
15
Cities with sites
Cities in Maryland
Baltimore 37Bethesda 16Elkton 4Glen Burnie 4Westminster 4Randallstown 3Columbia 2Towson 2Clinton 1Easton 1Ocean Pines 1Olney 1
Recruiting trials in Maryland
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- Cancer in Inherited Bone Marrow Failure Syndromes
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
- Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
- Diagnosing and Treating Low Blood Sugar Levels
- Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
- EXoPERT EMERALD Clinical Study
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Integrated Cancer Repository for Cancer Research
- Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
- LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
- NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
- Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
- Role of Genetic Factors in the Development of Lung Disease
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma